Common arthritis drug may boost fight against tough lymphoma
NCT ID NCT07494565
Summary
This study is testing if adding the anti-inflammatory drug celecoxib to the standard chemotherapy regimen (R-CHOP) works better for patients newly diagnosed with an aggressive form of lymphoma called CD5-positive DLBCL. It will involve 60 patients who will be randomly assigned to receive either the standard treatment or the standard treatment plus celecoxib. The main goal is to see if the combination leads to more patients achieving a complete disappearance of their cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Conditions
Explore the condition pages connected to this study.